News

Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...
Applied Clinical Trials Online1d

Phase III VAYHIT2 Trial Demonstrates Ianalumab Plus Eltrombopag Extends Disease Control in Primary Immune Thrombocytopenia

In the Phase III VAYHIT2 trial, ianalumab combined with eltrombopag significantly prolonged time to treatment failure and ...
Pharmabiz1d

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...
Clinical Trials Arena on MSN2d

Novartis scores again with third ianalumab Phase III victory

Novartis’ ianalumab has shown success in the third trial readout in two days, after it met both its endpoints in a Phase III ...
pharmaphorum2d

Novartis two for two as ianalumab scores again

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...
InvestorsHub on MSN2d

Novartis shares edge higher after ianalumab hits key goals in Phase 3 trial

Novartis (NYSE:NVS) announced that its investigational antibody, ianalumab, combined with eltrombopag, successfully met the ...

Novartis shares slightly up after Ianalumab meets goals in Phase 3 trial

Novartis (NYSE:NVS) (SIX:NOVN) said its experimental antibody ianalumab, used in combination with eltrombopag, achieved the ...

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...
MPR1d

Ianalumab Significantly Prolongs Time to Treatment Failure in Primary ITP

Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in adults with primary immune thrombocytopenia (ITP), a B cell-driven autoimmune disease, according to phase ...

Novartis Pharma AG: Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients ...